视网膜疾病中血管内皮生长因子抑制的概况
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases.
作者信息
Lin Joseph B, Apte Rajendra S
机构信息
John F. Hardesty, MD, Department of Ophthalmology and Visual Sciences, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States.
Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, United States.
出版信息
Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):47. doi: 10.1167/iovs.66.1.47.
Abstract
Ever since the US Food and Drug Administration (FDA) approved the first vascular endothelial growth factor (VEGF) antagonist 2 decades ago, inhibitors of VEGF have revolutionized the treatment of a variety of ocular disorders involving pathologic neovascularization and retinal exudation. In this perspective, we evaluate the current status of anti-VEGF therapies and the real-world challenges encountered with maintaining therapeutic outcomes. Finally, we describe novel VEGF-based and combinatorial approaches that are in clinical development.
摘要
自20年前美国食品药品监督管理局（FDA）批准首款血管内皮生长因子（VEGF）拮抗剂以来，VEGF抑制剂彻底改变了多种涉及病理性新生血管形成和视网膜渗出的眼部疾病的治疗方式。从这一角度出发，我们评估了抗VEGF疗法的现状以及维持治疗效果时所面临的现实挑战。最后，我们描述了正在临床开发中的基于VEGF的新型疗法和联合疗法。
相似文献
1
The Landscape of Vascular Endothelial Growth Factor Inhibition in Retinal Diseases.视网膜疾病中血管内皮生长因子抑制的概况
Invest Ophthalmol Vis Sci. 2025 Jan 2;66(1):47. doi: 10.1167/iovs.66.1.47.
2
A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.一种用于开发持续抗 VEGF 疗法的新型持续性视网膜新生血管模型。
Exp Eye Res. 2018 Sep;174:98-106. doi: 10.1016/j.exer.2018.05.027. Epub 2018 May 28.
3
[Progression and challenge of anti-vascular endothelial growth factor therapy in retinal neovascular disease].[视网膜新生血管疾病抗血管内皮生长因子治疗的进展与挑战]
Zhonghua Yan Ke Za Zhi. 2016 May;52(5):321-4. doi: 10.3760/cma.j.issn.0412-4081.2016.05.001.
4
Anti-vascular endothelial growth factor therapy for ocular neovascular disease.抗血管内皮生长因子疗法治疗眼部新生血管疾病。
Curr Opin Ophthalmol. 2007 Nov;18(6):502-8. doi: 10.1097/ICU.0b013e3282f0ca54.
5
Vascular endothelial growth factors in retinal and choroidal neovascular diseases.视网膜和脉络膜新生血管疾病中的血管内皮生长因子。
Ann Med. 2012 Feb;44(1):1-17. doi: 10.3109/07853890.2010.532150. Epub 2011 Feb 1.
6
Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（FGF-2）的双重阻断表现出强大的抗血管生成作用。
Cancer Lett. 2016 Jul 28;377(2):164-73. doi: 10.1016/j.canlet.2016.04.036. Epub 2016 Apr 26.
7
Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease.眼内抗血管内皮生长因子治疗眼部新生血管疾病的全身和眼部安全性。
Surv Ophthalmol. 2011 Mar-Apr;56(2):95-113. doi: 10.1016/j.survophthal.2010.08.006.
8
An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization.小儿视网膜疾病中血管内皮生长因子抑制作用的循证综述：第2部分。科茨病、最佳矫正视力疾病以及伴有儿童期新生血管形成的葡萄膜炎
J Pediatr Ophthalmol Strabismus. 2013 Jan-Feb;50(1):11-9. doi: 10.3928/01913913-20120821-02. Epub 2012 Aug 28.
9
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug.阿柏西普（VEGF Trap-eye）：最新的抗血管内皮生长因子药物。
Br J Ophthalmol. 2012 Sep;96(9):1157-8. doi: 10.1136/bjophthalmol-2011-300654. Epub 2012 Mar 23.
10
引用本文的文献
1
Evaluation of Anti-VEGFR2 Specific Photoimmunotherapy for Targeted Regression of Neovascularization in an AMD Model.在年龄相关性黄斑变性（AMD）模型中评估抗血管内皮生长因子受体2（VEGFR2）特异性光免疫疗法对新生血管靶向消退的作用。
Invest Ophthalmol Vis Sci. 2025 Jun 2;66(6):70. doi: 10.1167/iovs.66.6.70.
本文引用的文献
1
The impact of NF-κB on inflammatory and angiogenic processes in age-related macular degeneration.NF-κB 对年龄相关性黄斑变性中炎症和血管生成过程的影响。
Exp Eye Res. 2024 Nov;248:110111. doi: 10.1016/j.exer.2024.110111. Epub 2024 Sep 24.
2
Cholesterol Accumulation Promotes Photoreceptor Senescence and Retinal Degeneration.胆固醇积累促进光感受器衰老和视网膜变性。
Invest Ophthalmol Vis Sci. 2024 Aug 1;65(10):29. doi: 10.1167/iovs.65.10.29.
3
Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects.沃拉尼布、舒尼替尼和阿昔替尼：血管内皮生长因子受体抑制剂及其抗血管生成作用的比较研究。
PLoS One. 2024 Jun 4;19(6):e0304782. doi: 10.1371/journal.pone.0304782. eCollection 2024.
4
Subretinal hyperreflective material in regions of atrophy and fibrosis in eyes with neovascular age-related macular degeneration.新生血管性年龄相关性黄斑变性患者眼中萎缩和纤维化区域的视网膜下高反射物质。
Can J Ophthalmol. 2025 Feb;60(1):26-34. doi: 10.1016/j.jcjo.2024.05.007. Epub 2024 May 27.
5
Complement regulation in the eye: implications for age-related macular degeneration.补体调控与年龄相关性黄斑变性。
J Clin Invest. 2024 May 1;134(9):e178296. doi: 10.1172/JCI178296.
6
LXR/CD38 activation drives cholesterol-induced macrophage senescence and neurodegeneration via NAD depletion.LXR/CD38 激活通过 NAD 耗竭驱动胆固醇诱导的巨噬细胞衰老和神经退行性变。
Cell Rep. 2024 May 28;43(5):114102. doi: 10.1016/j.celrep.2024.114102. Epub 2024 Apr 17.
7
Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration.Wnt5a/β-catenin 介导的上皮-间充质转化：新生血管性年龄相关性黄斑变性中视网膜下纤维化的关键驱动因素。
J Neuroinflammation. 2024 Mar 26;21(1):75. doi: 10.1186/s12974-024-03068-w.
8
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial.玻璃体内注射阿柏西普 8mg 治疗新生血管性年龄相关性黄斑变性（PULSAR）：一项随机、双盲、非劣效性、3 期临床试验的 48 周结果。
Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7.
9
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.泰尼雅和卢塞恩：贝伐珠单抗生物类似药 faricimab 在湿性年龄相关性黄斑变性 2 年治疗和延长给药的 3 期临床试验的 2 年结果。
Ophthalmology. 2024 Aug;131(8):914-926. doi: 10.1016/j.ophtha.2024.02.014. Epub 2024 Feb 19.
10
Therapeutic targeting of cellular senescence in diabetic macular edema: preclinical and phase 1 trial results.治疗性靶向糖尿病性黄斑水肿中的细胞衰老：临床前和 1 期试验结果。
Nat Med. 2024 Feb;30(2):443-454. doi: 10.1038/s41591-024-02802-4. Epub 2024 Feb 6.
Zotero 插件